Pegylated liposomal doxorubicin for platinum-resistant or refractory Müllerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of Fallopian tube and peritoneal carcinoma): A single-institutional experience

Oncology Letters

Volumn 5, Issue 1, 2012, Pages 35-38

  Fukuda, Takeshi ^a   Sumi, Toshiyuki ^a   Teramae, Masatomo ^a   Nakano, Yusuke ^a   Morishita, Masanari ^a   Terada, Hiroyuki ^a   Yoshida, Hiroyuki ^a   Matsumoto, Yoshinari ^a   Yasui, Tomoyo ^a   Ishiko, Osamu ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

M llerian carcinoma; Ovarian carcinoma; Pegylated liposomal doxorubicin; Platinum resistance

Indexed keywords

DOXORUBICIN; PLATINUM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EPITHELIAL OVARIAN CARCINOMA; FEMALE; GYNECOLOGIC CANCER; HAND FOOT SYNDROME; HUMAN; MIXED MULLERIAN TUMOR; MULLERIAN CARCINOMA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PERITONEAL CARCINOMA; PRIMARY CARCINOMA OF FALLOPIAN TUBE; RETROSPECTIVE STUDY; STOMATITIS; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 84869040926     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.971     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Seewaldt VL, Greer BE, Cain JM, et al: Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial. Am J Obstet Gynecol 170: 1666-1670, 1994.
3. Neijt IP, ten Bokkel Huiniuk WW, van der Berg ME, et al: Long-term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 27: 1367-1372, 1991.
4. Dear RF, Gao B and Harnett P: Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre Experience. Asia Pac J Clin Oncol 6: 66-73, 2010.
5. Safra T, Groshen S, Jeffers S, Tsao-Wei DD, Zhou L, Muderspach L, Roman L, Morrow CP, Burnett A and Muggia FM: Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer 91: 90-100, 2001.
6. No authors listed: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta Analysis Project. J Clin Oncol 9: 1668-1674, 1991.
7. A'Hern RP and Gore ME: Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 13: 726-732, 1995.
8. Fanning J, Bennett TZ and Hilgers RD: Meta-analysis of cisplatin, doxorubicin and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 80: 954-960, 1992.
9. Singal PK and Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905, 1998.
10. Gabizon A and Martin F: Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumors. Drugs 54 (Suppl 4): 15-21, 1997.
11. Collins Y and Lele S: Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma. J Natl Med Assoc 97: 1414-1416, 2005.
12. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457, 1958.
13. Ferrandina G, Corrado G, Licameli A, Lorusso D, Fuoco G, Pisconti S and Scambia G: Pegylated liposomal doxorubicin in the management of ovarian cancer. Ther Clin Risk Manag 6: 463-483, 2010.
14. Gladieff L, Ferrero A, De Rauglaudre G, et al: Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Ann Oncol 5: 1185-1189, 2011.
15. Kurtz JE, Kaminsky MC, Floquet A, et al: Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCGI) CALYPSO sub-study. Ann Oncol 22: 2417-2423, 2011.
16. Gordon AN, Granai CO, Rose PG, et al: Phase II study of stealth liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18: 3093-3100, 2000.
17. Johnston SRD and Gore ME: Caelyx: phase II studies in ovarian cancer. Eur J Cancer 37 (Suppl 9): S8-S14, 2001.
18. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME and Lacave AJ: Recurrent epithelial ovarian carcinoma: a randomized phase II study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312-3322, 2001.
19. Katsumata N, Fujiwara Y, Kamura T, et al: Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with Müllerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: A phase II study of the Japanese Gynecologic Oncology Group. Jpn J Clin Oncol 38: 777-785, 2008.
20. Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15: 987-993, 1997.
21. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore M, Lacave AJ and Mutch D: Interim analysis of a phase III randomized trial of doxil/caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer. Proc Am Soc Clin Oncol: 9: 380, 2000.